Revolution Medicines, Inc. (RVMD): who owns it and who trades it
As of Nov 16, 2026, RVMD insiders reported 167 open-market sales worth $157M and no purchases in the last 12 months, with 5% of the sale value made under pre-set 10b5-1 plans. The largest seller was Mark A Goldsmith (Director), with $52.6M. 6 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Revolution Medicines
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns RVMD
687 funds and institutions reported RVMD shares worth $40.5B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 6.4%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 13.70M | 6.44% | $2.6B | +22% |
| Farallon Capital Management, L.l.c. | 13.55M | 6.37% | $2.5B | -0% |
| FMR LLC (Fidelity) | 12.20M | 5.74% | $2.3B | +44% |
| Baker Bros. Advisors LP | 11.44M | 5.38% | $2.1B | +20% |
| Jupiter Topco LLC | 10.74M | 5.05% | $2B | – |
| Darwin Global Management, Ltd. | 10.63M | 5.00% | $2B | +381% |
| Vanguard Capital Management LLC | 9.09M | 4.28% | $1.7B | +9% |
| Vanguard Portfolio Management LLC | 8.29M | 3.90% | $1.6B | +11% |
| Nextech Invest Ltd. | 7.60M | 3.58% | $1.4B | No change |
| Paradigm Biocapital Advisors LP | 6.36M | 2.99% | $1.2B | -4% |
| UBS Group AG | 5.45M | 2.56% | $1B | +24% |
| State Street Corp | 4.90M | 2.30% | $917M | +11% |
| Capital World Investors | 4.01M | 1.89% | $751M | – |
| Geode Capital Management, LLC | 3.94M | 1.85% | $737M | +18% |
| Wellington Management Group LLP | 3.84M | 1.81% | $720M | -36% |
| JPMorgan Chase & Co | 3.30M | 1.55% | $637M | – |
| Bvf Inc | 2.97M | 1.39% | $555M | +4% |
| Alphabet Inc. | 2.95M | 1.39% | $552M | -11% |
| Casdin Capital, LLC | 2.58M | 1.21% | $483M | No change |
| Deerfield Management Company, L.P. | 2.39M | 1.13% | $448M | +4% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, RVMD insiders reported $0 of open-market purchases and $157M of sales. 5% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 11, 2026 | Jack Anders | CFO | Sale plan | 3,499 | $181.04 | $633K | Form 4 |
| Nov 11, 2026 | Jack Anders | CFO | Sale plan | 5,776 | $182.09 | $1.1M | Form 4 |
| Nov 11, 2026 | Jack Anders | CFO | Sale plan | 2,700 | $182.87 | $494K | Form 4 |
| Nov 11, 2026 | Jack Anders | CFO | Sale plan | 1,900 | $184.02 | $350K | Form 4 |
| Nov 11, 2026 | Jack Anders | CFO | Sale plan | 800 | $185.04 | $148K | Form 4 |
| Nov 11, 2026 | Jack Anders | CFO | Sale plan | 400 | $186.41 | $74.6K | Form 4 |
| Nov 11, 2026 | Jack Anders | CFO | Sale plan | 600 | $187.34 | $112K | Form 4 |
| Nov 11, 2026 | Jack Anders | CFO | Sale plan | 200 | $189.17 | $37.8K | Form 4 |
| Nov 11, 2026 | Jack Anders | CFO | Sale plan | 500 | $190.99 | $95.5K | Form 4 |
| Nov 11, 2026 | Jack Anders | CFO | Sale plan | 9,486 | $191.94 | $1.8M | Form 4 |
| Nov 11, 2026 | Jack Anders | CFO | Sale plan | 9,889 | $192.84 | $1.9M | Form 4 |
| Nov 9, 2026 | Anthony Mancini | See Remarks | Sale plan | 811 | $200.00 | $162K | Form 4 |
| Oct 26, 2026 | Anthony Mancini | See Remarks | Sale plan | 2,310 | $186.99 | $432K | Form 4 |
| Sep 29, 2026 | Alan B. Sandler | Chief Development Office | Sale plan | 2,200 | $200.82 | $442K | Form 4 |
| Sep 29, 2026 | Alan B. Sandler | Chief Development Office | Sale plan | 1,609 | $201.72 | $325K | Form 4 |
| Sep 29, 2026 | Alan B. Sandler | Chief Development Office | Sale plan | 1,000 | $202.81 | $203K | Form 4 |
| Sep 29, 2026 | Alan B. Sandler | Chief Development Office | Sale plan | 1,199 | $203.91 | $244K | Form 4 |
| Sep 29, 2026 | Alan B. Sandler | Chief Development Office | Sale plan | 301 | $204.72 | $61.6K | Form 4 |
| Sep 25, 2026 | Jeff Cislini | Vice president | Sale | 765 | $207.32 | $159K | Form 4 |
| Sep 25, 2026 | Anthony Mancini | See Remarks | Sale | 3,121 | $200.54 | $626K | Form 4 |
| Sep 24, 2026 | Anthony Mancini | See Remarks | Sale | 587 | $200.00 | $117K | Form 4 |
| Sep 22, 2026 | Elizabeth M Anderson | Director | Sale | 100 | $195.15 | $19.5K | Form 4 |
| Sep 22, 2026 | Elizabeth M Anderson | Director | Sale | 2,648 | $193.44 | $512K | Form 4 |
| Sep 22, 2026 | Elizabeth M Anderson | Director | Sale | 4,985 | $192.54 | $960K | Form 4 |
| Sep 22, 2026 | Elizabeth M Anderson | Director | Sale | 910 | $191.85 | $175K | Form 4 |
| Sep 22, 2026 | Elizabeth M Anderson | Director | Sale | 1,500 | $194.59 | $292K | Form 4 |
| Sep 18, 2026 | Anthony Mancini | See Remarks | Sale | 1,764 | $196.94 | $347K | Form 4 |
| Sep 16, 2026 | Alan B. Sandler | Chief Development Office | Sale | 336 | $199.30 | $67K | Form 4 |
| Sep 16, 2026 | Alan B. Sandler | Chief Development Office | Sale | 5 | $194.96 | $975 | Form 4 |
| Sep 16, 2026 | Anthony Mancini | See Remarks | Sale | 1,747 | $199.30 | $348K | Form 4 |
| Sep 16, 2026 | Anthony Mancini | See Remarks | Sale | 27 | $195.05 | $5.3K | Form 4 |
| Sep 16, 2026 | Stephen Michael Kelsey | See Remarks | Sale | 85 | $195.01 | $16.6K | Form 4 |
| Sep 16, 2026 | Stephen Michael Kelsey | See Remarks | Sale | 5,484 | $199.30 | $1.1M | Form 4 |
| Sep 16, 2026 | Margaret A Horn | Chief Operating Officer | Sale | 4,891 | $199.30 | $975K | Form 4 |
| Sep 16, 2026 | Margaret A Horn | Chief Operating Officer | Sale | 76 | $195.01 | $14.8K | Form 4 |
| Sep 16, 2026 | Mark A Goldsmith | Director | Sale | 213 | $195.01 | $41.5K | Form 4 |
| Sep 16, 2026 | Mark A Goldsmith | Director | Sale | 13,775 | $199.30 | $2.7M | Form 4 |
| Sep 16, 2026 | Jeff Cislini | Vice president | Sale | 52 | $195.01 | $10.1K | Form 4 |
| Sep 16, 2026 | Jeff Cislini | Vice president | Sale | 3,314 | $199.30 | $660K | Form 4 |
| Sep 16, 2026 | Jack Anders | CFO | Sale | 3,992 | $199.30 | $796K | Form 4 |
| Sep 16, 2026 | Jack Anders | CFO | Sale | 61 | $195.00 | $11.9K | Form 4 |
| Sep 11, 2026 | Stephen Michael Kelsey | See Remarks | Sale | 3,270 | $205.81 | $673K | Form 4 |
| Sep 11, 2026 | Stephen Michael Kelsey | See Remarks | Sale | 4,995 | $204.84 | $1M | Form 4 |
| Sep 11, 2026 | Stephen Michael Kelsey | See Remarks | Sale | 17,949 | $203.87 | $3.7M | Form 4 |
| Sep 11, 2026 | Stephen Michael Kelsey | See Remarks | Sale | 18,869 | $203.06 | $3.8M | Form 4 |
| Sep 11, 2026 | Stephen Michael Kelsey | See Remarks | Sale | 21,447 | $201.75 | $4.3M | Form 4 |
| Sep 11, 2026 | Stephen Michael Kelsey | See Remarks | Sale | 13,368 | $200.78 | $2.7M | Form 4 |
| Sep 11, 2026 | Stephen Michael Kelsey | See Remarks | Sale | 11,833 | $200.11 | $2.4M | Form 4 |
| Sep 11, 2026 | Stephen Michael Kelsey | See Remarks | Sale | 800 | $198.55 | $159K | Form 4 |
| Sep 10, 2026 | Anthony Mancini | See Remarks | Sale | 2,420 | $205.05 | $496K | Form 4 |
| Sep 10, 2026 | Anthony Mancini | See Remarks | Sale | 1,179 | $206.10 | $243K | Form 4 |
| Sep 10, 2026 | Anthony Mancini | See Remarks | Sale | 300 | $207.17 | $62.2K | Form 4 |
| Sep 10, 2026 | Anthony Mancini | See Remarks | Sale | 6,019 | $203.28 | $1.2M | Form 4 |
| Sep 10, 2026 | Anthony Mancini | See Remarks | Sale | 5,530 | $204.14 | $1.1M | Form 4 |
| Sep 8, 2026 | Lorence H. Kim | Director | Sale | 706 | $206.60 | $146K | Form 4 |
| Sep 8, 2026 | Lorence H. Kim | Director | Sale | 999 | $207.33 | $207K | Form 4 |
| Sep 8, 2026 | Lorence H. Kim | Director | Sale | 3,587 | $208.55 | $748K | Form 4 |
| Sep 8, 2026 | Lorence H. Kim | Director | Sale | 371 | $212.27 | $78.8K | Form 4 |
| Sep 8, 2026 | Lorence H. Kim | Director | Sale | 4,730 | $210.50 | $996K | Form 4 |
| Sep 8, 2026 | Lorence H. Kim | Director | Sale | 3,844 | $211.36 | $812K | Form 4 |
| Sep 8, 2026 | Lorence H. Kim | Director | Sale | 2,853 | $209.56 | $598K | Form 4 |
| Aug 31, 2026 | Lorence H. Kim | Director | Sale | 625 | $206.15 | $129K | Form 4 |
| Aug 31, 2026 | Lorence H. Kim | Director | Sale | 300 | $200.56 | $60.2K | Form 4 |
| Aug 31, 2026 | Lorence H. Kim | Director | Sale | 6,597 | $201.47 | $1.3M | Form 4 |
| Aug 31, 2026 | Lorence H. Kim | Director | Sale | 26,160 | $203.55 | $5.3M | Form 4 |
| Aug 31, 2026 | Lorence H. Kim | Director | Sale | 7,271 | $204.35 | $1.5M | Form 4 |
| Aug 31, 2026 | Lorence H. Kim | Director | Sale | 12,919 | $202.48 | $2.6M | Form 4 |
| Aug 31, 2026 | Lorence H. Kim | Director | Sale | 2,128 | $205.19 | $437K | Form 4 |
| Aug 21, 2026 | Jeff Cislini | General Counsel | Sale | 2,540 | $210.26 | $534K | Form 4 |
| Aug 21, 2026 | Jeff Cislini | General Counsel | Sale | 3,314 | $212.06 | $703K | Form 4 |
| Aug 21, 2026 | Jeff Cislini | General Counsel | Sale | 4,500 | $211.34 | $951K | Form 4 |
| Aug 21, 2026 | Jeff Cislini | General Counsel | Sale | 3,400 | $207.24 | $705K | Form 4 |
| Aug 21, 2026 | Jeff Cislini | General Counsel | Sale | 25,817 | $209.25 | $5.4M | Form 4 |
| Aug 21, 2026 | Jeff Cislini | General Counsel | Sale | 17,323 | $208.37 | $3.6M | Form 4 |
| Aug 21, 2026 | Mark A Goldsmith | Director | Sale | 245 | $211.47 | $51.8K | Form 4 |
| Aug 21, 2026 | Mark A Goldsmith | Director | Sale | 229 | $211.46 | $48.4K | Form 4 |
| Aug 21, 2026 | Mark A Goldsmith | Director | Sale | 126 | $210.40 | $26.5K | Form 4 |
| Aug 21, 2026 | Mark A Goldsmith | Director | Sale | 1,405 | $209.27 | $294K | Form 4 |
| Aug 21, 2026 | Mark A Goldsmith | Director | Sale | 937 | $208.36 | $195K | Form 4 |
| Aug 21, 2026 | Mark A Goldsmith | Director | Sale | 177 | $207.25 | $36.7K | Form 4 |
| Aug 21, 2026 | Mark A Goldsmith | Director | Sale | 127 | $212.06 | $26.9K | Form 4 |
| Aug 21, 2026 | Mark A Goldsmith | Director | Sale | 126 | $212.06 | $26.7K | Form 4 |
| Aug 21, 2026 | Mark A Goldsmith | Director | Sale | 5,128 | $207.23 | $1.1M | Form 4 |
| Aug 21, 2026 | Mark A Goldsmith | Director | Sale | 24,917 | $208.37 | $5.2M | Form 4 |
| Aug 21, 2026 | Mark A Goldsmith | Director | Sale | 35,938 | $209.26 | $7.5M | Form 4 |
| Aug 21, 2026 | Mark A Goldsmith | Director | Sale | 3,813 | $210.25 | $802K | Form 4 |
| Aug 21, 2026 | Mark A Goldsmith | Director | Sale | 6,583 | $211.33 | $1.4M | Form 4 |
| Aug 21, 2026 | Mark A Goldsmith | Director | Sale | 3,621 | $212.08 | $768K | Form 4 |
| Aug 21, 2026 | Mark A Goldsmith | Director | Sale | 190 | $207.25 | $39.4K | Form 4 |
| Aug 21, 2026 | Mark A Goldsmith | Director | Sale | 951 | $208.36 | $198K | Form 4 |
| Aug 21, 2026 | Mark A Goldsmith | Director | Sale | 1,351 | $209.28 | $283K | Form 4 |
| Aug 21, 2026 | Mark A Goldsmith | Director | Sale | 136 | $210.40 | $28.6K | Form 4 |
| Jun 29, 2026 | Sushil Patel | Director | Sale | 300 | $183.17 | $55K | Form 4 |
| Jun 29, 2026 | Sushil Patel | Director | Sale | 900 | $184.59 | $166K | Form 4 |
| Jun 29, 2026 | Sushil Patel | Director | Sale | 1,100 | $185.90 | $204K | Form 4 |
| Jun 29, 2026 | Sushil Patel | Director | Sale | 881 | $192.61 | $170K | Form 4 |
| Jun 29, 2026 | Sushil Patel | Director | Sale | 300 | $187.83 | $56.3K | Form 4 |
| Jun 29, 2026 | Sushil Patel | Director | Sale | 100 | $188.57 | $18.9K | Form 4 |
| Jun 29, 2026 | Sushil Patel | Director | Sale | 600 | $190.55 | $114K | Form 4 |
| Jun 29, 2026 | Sushil Patel | Director | Sale | 541 | $191.87 | $104K | Form 4 |
Latest 100 of 167 trades in the last 12 months.
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Mark A Goldsmith | See Remarks, Director | – | $52.6M | Sep 16, 2026 |
| Margaret A Horn | Chief Operating Officer | – | $25.3M | Sep 16, 2026 |
| Stephen Michael Kelsey | See Remarks | – | $21.3M | Sep 16, 2026 |
| Lorence H. Kim | Director | – | $15M | Sep 8, 2026 |
| Jeff Cislini | General Counsel | – | $14.6M | Sep 25, 2026 |
| Jack Anders | Chief Financial Officer | – | $13.2M | Nov 11, 2026 |
| Anthony Mancini | See Remarks | – | $10.4M | Nov 9, 2026 |
| Elizabeth M Anderson | Director | – | $2M | Sep 22, 2026 |
| Alan B. Sandler | Chief Development Officer | – | $1.3M | Sep 29, 2026 |
| Sushil Patel | Director | – | $1M | Jun 29, 2026 |
| Lin Wei | Chief Medical Officer | – | $206K | Mar 17, 2026 |
| Xiaolin Wang | See Remarks | – | $200K | Mar 17, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
RVMD short interest
Moderate short interest. 6.0% of RVMD shares are sold short: about 1 share in 17. Over the last 12 reports the number of shares short went up 18%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 13.08M RVMD shares were sold short, 6.0% of the shares outstanding, up 1.1% from the report before. At the average daily volume of 1.69M shares, buying them all back would take about 7.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 13.08M | 6.05% | +1% | 1.69M | 7.8 |
| Oct 15, 2026 | 12.93M | 6.03% | +8% | 2.11M | 6.1 |
| Sep 30, 2026 | 11.93M | 5.56% | +23% | 2.56M | 4.7 |
| Sep 15, 2026 | 9.67M | 4.51% | -1% | 1.33M | 7.2 |
| Aug 31, 2026 | 9.73M | 4.54% | +0% | 2.08M | 4.7 |
| Aug 14, 2026 | 9.72M | 4.53% | -16% | 1.53M | 6.4 |
| Jul 31, 2026 | 11.52M | 5.37% | -18% | 1.83M | 6.3 |
| Jul 15, 2026 | 14.00M | 6.59% | +9% | 2.06M | 6.8 |
| Jun 30, 2026 | 12.88M | 6.06% | +5% | 4.31M | 3.0 |
| Jun 15, 2026 | 12.28M | 5.78% | +6% | 2.85M | 4.3 |
| May 29, 2026 | 11.59M | 5.45% | +5% | 2.75M | 4.2 |
| May 15, 2026 | 11.08M | 5.21% | -13% | 2.35M | 4.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Revolution Medicines company events
Revolution Medicines filed 11 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Oct 13, 2026AnnouncementBelow under the heading “Royalty Pharma Tranche A Loan” is incorporated by reference into this Item 2.03. Filing
- Sep 1, 2026AgreementRevolution Medicines, Inc. agreed to lease the entirety of four buildings located at 1600, 1700, 1800 and 1900 Seaport Boulevard in Redwood City, California, comprising an aggregate of approximately 672,000 rentable square feet. Filing
- Aug 26, 2026AnnouncementThe U.S. Food and Drug Administration approved RASONQUE™ (daraxonrasib) for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jun 22, 2026LeadershipSteve Kelsey, M.D., FRCP, FRCPath, informed Revolution Medicines, Inc. of his intent to retire from his employment with the Company effective as of January 4, 2027. Filing
- May 6, 2026ResultsReleased financial results. Filing
- Apr 17, 2026AgreementRevolution Medicines, Inc. issued $500 million of its 0.50% Convertible Senior Notes due 2033. Filing
- Apr 16, 2026AnnouncementRevolution Medicines, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein, to issue and sell 10,563,381 shares of the Company’s common stock, $0.0001 par… Filing
- Apr 13, 2026AnnouncementRevolution Medicines, Inc. shared topline results from its global, randomized, controlled Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma who had been previously treated. Filing
- Feb 25, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Revolution Medicines financials
Famous investors that hold RVMD
6 of the 50 well-known investors we track reported holding RVMD in their latest 13F filing. The largest position is Ken Griffin's, worth $269M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.31M | $269M | 0.1% | +122% |
| Stanley Druckenmiller · Duquesne Family Office | Q3 2026 | 436,287 | $89.6M | 2.2% | +9% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 212,971 | $43.7M | 0.1% | +253% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 134,686 | $27.6M | 0.0% | -35% |
| Israel Englander · Millennium Management | Q3 2026 | 81,236 | $16.7M | 0.0% | -62% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 16,000 | $3.3M | 0.0% | No change |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named RVMD in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Baker Bros. Advisors LP | 13G/A | 4.9% |
| Nov 16, 2026 | JANUS HENDERSON GROUP Ltd. | 13G/A | 3.5% |
| Nov 16, 2026 | Baker Bros. Advisors LP | 13G/A | 4.9% |
| Nov 16, 2026 | JANUS HENDERSON GROUP Ltd. | 13G/A | 3.5% |
| Nov 5, 2026 | FMR LLC | 13G/A | 7.2% |
| Nov 5, 2026 | FMR LLC | 13G/A | 7.2% |
| Oct 30, 2026 | Vanguard Capital Management | 13G | 5.1% |
| Oct 30, 2026 | Vanguard Capital Management | 13G | 5.1% |
Questions about Revolution Medicines, Inc. (RVMD) stock
Who owns the most RVMD stock?
The largest reported owner of Revolution Medicines, Inc. (RVMD) is BlackRock, Inc., with 6.4% of the company. In total, 687 funds and institutions reported holding RVMD at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are RVMD insiders buying or selling?
In the last 12 months, RVMD insiders reported no open-market purchases and 167 sales worth $157M. The latest trade was on Nov 11, 2026. See every trade.
What is the short interest in RVMD?
As of Oct 30, 2026, 13.08M RVMD shares were sold short, 6.0% of the shares outstanding, up 1.1% from the report before. At the average daily volume of 1.69M shares, buying them all back would take about 7.8 trading days (days to cover). See the history.
Which famous investors hold RVMD?
6 of the 50 well-known investors we track reported RVMD in their latest 13F filing, including Ken Griffin, Stanley Druckenmiller, Steve Cohen. The largest position is worth $269M. See all holders.
Executive pay
Revolution Medicines's chief executive was paid a total of $14.7M for the year ended Dec 31, 2025, up 46% from $10.1M the year before. In the last 12 months, Revolution Medicines's executives and directors bought no stock on the open market and sold $158M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.